about
Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanomaComparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathwayMelanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.Whole-genome landscapes of major melanoma subtypes.Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.Identification of new prognostic biomarkers for Stage III metastatic melanoma patientsPD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsPD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trialsHow anti-PD1 treatments are changing the management of melanoma.
P50
Q30403025-CAF81657-1482-419D-ADC6-8745E89BE840Q33918101-A0FF4E90-1EE9-405F-BCA1-896B68161B82Q34299814-8CB25886-4328-4053-B4E0-68C8C5922FCDQ35971923-438A8B6D-EA44-4F10-B103-FA122ADF63BFQ36109039-388A3761-ABA0-4AE1-AE40-1C0FC0475F6FQ38395528-36893CE4-3546-4BB5-ADDE-602501BFC1B7Q38791332-7D28FCE2-D24E-4608-88D5-C1579435F6B4Q39060449-7E6F1F06-D765-4E9F-965D-D677D442B452Q41120940-12789974-D266-4C12-92DE-13291439C2ECQ41320696-6E57A77F-40E1-4B84-B199-C8F6EA745957Q41762179-71F56051-6644-4F40-A8CE-98C830752207Q47573421-368AD2FA-CC15-4F89-838D-0D32BFB6B059Q47759472-BB50FC96-4A7B-4F3B-8609-6FCF457A082DQ48703829-43C52132-74D2-46BC-A961-3E5193118E21Q50783299-EEC93183-836A-4DB3-8E46-77687E987BA9Q50853051-F724A20B-135A-4419-808E-48B5ECD4491DQ52681406-AA7D850E-E06E-4950-A6F5-851C24BD5180Q54195782-D4A9A272-5B43-414A-AF66-2AD7B3B469E5Q54369767-A81654C5-4DEB-445D-90E0-3049EF71B057Q57261157-8C559407-94DB-4D33-9D1D-8FEB74C8364AQ58024555-E3A89C77-4821-4E2F-AFB4-0978A98849F6Q64978186-BE91AF81-23A7-492C-B0DC-2BD6D254454B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hojabr Kakavand
@ast
Hojabr Kakavand
@en
Hojabr Kakavand
@es
Hojabr Kakavand
@nl
type
label
Hojabr Kakavand
@ast
Hojabr Kakavand
@en
Hojabr Kakavand
@es
Hojabr Kakavand
@nl
prefLabel
Hojabr Kakavand
@ast
Hojabr Kakavand
@en
Hojabr Kakavand
@es
Hojabr Kakavand
@nl
P106
P1153
55360426400
P31
P496
0000-0002-3458-7853